The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients.
Conclusions: The use of HCQ is independently associated with decreased risk for cardiovascular morbidity among RA patients, particularly with a higher dose of 400 mg per day. This newly demonstrated effect of HCQ should be considered in the overall management of RA.
PMID: 29464097 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Heart | Hydroxychloroquine | Rheumatoid Arthritis | Rheumatology | Study